Who founded Kira Pharmaceuticals?

Kira Pharmaceuticals was founded by Wenru Song.

Who are Kira Pharmaceuticals's investors?

Kira Pharmaceuticals's investors include Foresite Capital, Quan Capital, Vivo Capital, Ikarian Capital.

Where is Kira Pharmaceuticals headquartered?

Kira Pharmaceuticals is headquartered in Cambridge, US.

Kira Pharmaceuticals

Cambridge, US · 5 known investors

Find your way into Kira Pharmaceuticals

309 people in our graph share verified history with the Kira Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.

David Kaufmanunlockedknows Wenru Song · together at Joan & Sanford I. Weill Medical College of Cornell University (overlapped)

×2knows the team · via AstraZeneca

×2knows the team · via Texas A&M University

knows the team · via Shandong University

knows the team · via Millennium: The Takeda Oncology Company

×3knows the team · via Stanford University School of Medicine

Kira Pharmaceuticals is a biotech company developing therapies targeting complement biology to treat complement-mediated diseases. Its work combines drug development and protein engineering, supported by academic collaborators and a scientific advisory board in complement biology and immunology.

Biotech Healthtech

Founders & leadership

Wenru Song inCo-Founder, President and Head of R&DWenru Song is a board-certified medical oncologist with background in academic clinical and translational research and pharmaceutical drug development. She founded Kira Pharmaceuticals, a biotech company developing complement-targeted therapies for complement-mediated diseases.

Investors · 5

Foresite CapitalWest Hollywood

Quan CapitalShanghai

Vivo CapitalPalo Alto · $10M – $50M

Ikarian CapitalreportedDallas

Also in the syndicate · 1

Affinity Asset Advisorslead

In the news

Jasper Therapeutics Reports Q2 2026 Results and Completion of Kira Pharmaceuticals Acquisition | Quiver Quantitativequiverquant.com · Aug 2026

Jasper Therapeutics, Inc. (JSPR) stock: Climbs on Kira Merger and $132M Raise as Pipeline Consolidatesblockonomi.com · Aug 2026

Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement | PharmExecpharmexec.com · Aug 2026

Jasper Therapeutics Completes Kira Pharmaceuticals Acquisition and Announces $132 Million Private Placement and KP-301/KP-402 Out-Licensing to Mirador Therapeutics | Quiver Quantitativequiverquant.com · Jul 2026

Kira and its complement-target inhibitors plot run to the clinic with new investor cash just months after uncloaking - Penn Center for Innovationpci.upenn.edu · Jan 2021

Kira Pharmaceuticals Announces $53.5 Million Series B+ Financing to Advance LOGIC Drug Discovery Platform and Pipeline of Complement-targeted Therapiesprnewswire.com · Jan 2021

Frequently asked questions

What does Kira Pharmaceuticals do?: Kira Pharmaceuticals is a biotech company developing therapies targeting complement biology to treat complement-mediated diseases. Its work combines drug development and protein engineering, supported by academic collaborators and a scientific advisory board in complement biology and immunology.
Who founded Kira Pharmaceuticals?: Kira Pharmaceuticals was founded by Wenru Song.
Who are Kira Pharmaceuticals's investors?: Kira Pharmaceuticals's investors include Foresite Capital, Quan Capital, Vivo Capital, Ikarian Capital.
Where is Kira Pharmaceuticals headquartered?: Kira Pharmaceuticals is headquartered in Cambridge, US.